Relative Cerebral Blood Volume of Tumor Habitats Can Differentiate Presurgical IDH-wildtype Glioblastoma from IDH-mutant Astrocytoma Grade 4.

IDH -wildtype glioblastoma and IDH -mutant astrocytoma are classified as different gliomas according to WHO 2021. IDH mutations are key at clinical level, since they are associated with patient prognosis and seem to be critical for treatment selection. Despite these evidences, current protocols do not include the full sequencing for all tumors. In this sense, non-invasive and automatically calculated MRI-based biomarkers can be helpful for the clinical practice. Our results show that perfusion markers obtained in an automated, repeatable, and non-invasive manner may be candidates for being surrogate predictive markers of IDH mutation status in astrocytomas grade 4.